FGFR1OP-FGFR1

FGFR1OP-FGFR1 · Variant type: fusion · Fusion partner: FGFR1

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Alpelisib	100.0%	0.0%	97.22
2	Futibatinib	100.0%	0.0%	98.48
3	Pemigatinib	99.4%	0.6%	98.23
4	Infigratinib	99.1%	0.9%	98.24
5	Erdafitinib	99.0%	0.9%	95.71
6	Ponatinib	98.2%	1.8%	78.23
7	Pralsetinib	97.0%	3.0%	93.43
8	Tenalisib	96.8%	3.2%	97.98
9	Deucravacitinib	94.8%	5.2%	98.99
10	Nintedanib	94.3%	5.7%	90.23
11	Brigatinib	93.5%	6.5%	82.96
12	Axitinib	92.5%	7.5%	93.23
13	Lenvatinib	92.2%	7.8%	97.74
14	Selpercatinib	90.4%	9.6%	96.72
15	Pazopanib	83.6%	16.4%	97.49
16	Regorafenib	82.4%	17.6%	95.99
17	Ripretinib	81.4%	18.6%	92.95
18	Tepotinib	79.8%	20.2%	99.75
19	Ibrutinib	75.6%	24.4%	94.74
20	Vandetanib	71.8%	28.2%	95.74
21	Pacritinib	61.1%	38.9%	88.64
22	Repotrectinib	60.9%	39.1%	84.21
23	Entrectinib	58.7%	41.3%	93.69
24	Tivozanib	55.5%	44.5%	92.42
25	Sunitinib	55.5%	44.5%	91.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Alpelisib	100.0%	—	—
Futibatinib	100.0%	—	—
Pemigatinib	99.4%	—	—
Infigratinib	99.1%	—	—
Erdafitinib	99.0%	—	—
Ponatinib	98.2%	—	—
Pralsetinib	97.0%	—	—
Tenalisib	96.8%	—	—
Deucravacitinib	94.8%	—	—
Nintedanib	94.3%	—	—
Brigatinib	93.5%	—	—
Axitinib	92.5%	—	—
Lenvatinib	92.2%	—	—
Selpercatinib	90.4%	—	—
Pazopanib	83.6%	—	—
Regorafenib	82.4%	—	—
Ripretinib	81.4%	—	—
Tepotinib	79.8%	—	—
Ibrutinib	75.6%	—	—
Vandetanib	71.8%	—	—
Pacritinib	61.1%	—	—
Repotrectinib	60.9%	—	—
Entrectinib	58.7%	—	—
Tivozanib	55.5%	—	—
Sunitinib	55.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms